Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5152W HIGH $26.58
Volume
57.24 K
Value Traded
67.88 K
Short % Float
0.59%
Days to Cover
1.0
+2.41%Week
-34.01%1 Month
-37.13%3 Month
-68.24%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.54 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-548.33 K
Total Shares
2.51 M
Float Shares
4.49 M
Insiders
5.96%
Institutions
4.44%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
IVF Catalyst Timeline
Dated clinical, regulatory and corporate events for INVO Fertility, Inc.
Past FDA Catalysts and PDUFA Decisions
How IVF actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
INVO Fertility, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every IVF program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IVF outcomes | 2026-08-20 | Among 19 patients, those younger than 35 years (n = 3) demonstrated the most robust improvements in ovarian response, including higher oocyte yield and improved embryo development.; Patients ages 35-39 (n = 9) showed moderate but generally consistent improvements.; Patients age 40 and older (n = 7) experienced more limited responses and continued to demonstrate high rates of aneuploidy.; In a 19-patient analysis in which each patient served as her own control, the study reported an overall increase in high-quality blastocyst development following PRP.; Two patients moved from producing no euploid embryos to producing multiple euploid embryos in subsequent cycles.; Two patients conceived spontaneously while preparing for additional IVF treatment.Read More | INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium InternationalRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Szot Matthew KDirector | Sell | -4 3 held | $1.52 | 12/03/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in IVF
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IVF for Q2 2026. | ||||
IVF Institutional Ownership Trends
IVF Short Interest
Shares sold short, counted twice a month.
0.59%
Short % of Float
of tradable shares sold short
26.5K
Shares Sold Short
-47.2% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
140.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IVF ranks across every disease it competes in
Competitive Position is a premium feature
See how IVF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIVF News
-IVF
Oct 27, 2026▲ +7%today
INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026
INVO Fertility announced a 1-for-4 reverse stock split effective October 30, 2026. The company's common stock will trade under the same symbol, 'IVF', post-split. After the split, approximately 1,192,841 shares will be outstanding, and authorized shares will adjust to 62,500,000. This move aims to strengthen the company's market presence.
Read more →-IVF
Sep 25, 2026INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference
INVO Fertility, Inc. will participate in the Lytham Partners Fall 2026 Investor Conference on September 29-30, 2026. The company will host a webcast presentation and engage in one-on-one meetings with investors. INVO Fertility focuses on expanding access to assisted reproductive technology and operates four fertility clinics in the U.S.
Read more →-IVF
Aug 28, 2026INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
INVO Fertility, Inc. will participate in the 28th Annual H.C. Wainwright Global Investment Conference from September 14-16, 2026. The company will provide a pre-recorded presentation starting September 11, 2026, and will hold one-on-one meetings with investors during the event. INVO Fertility focuses on expanding access to assisted reproductive technology through its clinics and innovative products.
Read more →-IVF
Aug 20, 2026INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International
INVO Fertility announced that Dr. Gretchen Collins presented five poster abstracts at the 2026 Midwest Reproductive Symposium. The studies focused on the effects of platelet-rich plasma (PRP) on IVF outcomes, showing promising results in improving ovarian response and embryo development in patients with prior poor outcomes. The findings support further investigation into PRP therapy as a viable option for enhancing fertility treatments.
Read more →-IVF
Aug 17, 2026▲ +57.5%on this newsshared move
INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
INVO Fertility reported a 17% increase in revenue for Q2 2026, driven by organic growth and acquisitions. The clinic platform achieved profitability on an Adjusted EBITDA basis, highlighting operational improvements. The company successfully acquired the Birmingham clinic, enhancing its operational control. Despite these positives, it reported a loss from operations and negative Adjusted EBITDA.
Read more →-IVF
Jun 22, 2026▼ -7.3%on this news
INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
INVO Fertility reported a strong financial performance for Q1 2026, achieving a 23% increase in revenue compared to the previous year. The company eliminated its Series C-2 Preferred Stock and warrant liabilities, significantly improving its balance sheet. Despite a net loss from continuing operations, the overall outlook remains positive due to strategic growth initiatives and acquisitions.
Read more →-IVF
Jun 2, 2026INVO Fertility Announces Fiscal Year 2025 Financial Results
INVO Fertility, Inc. reported a 5% increase in revenue for FY2025, reaching $6.84 million. The company successfully acquired Family Beginnings, expanding its clinic network to four locations. Despite a net loss of $5.3 million, INVO Fertility strengthened its balance sheet through significant financing and continued innovation in reproductive technology. Management expresses optimism for future growth.
Read more →-IVF
Jun 2, 2026INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q
INVO Fertility, Inc. received a notice from Nasdaq regarding its late filing of the 10-K and 10-Q reports. The company is currently working to resolve these issues and has filed the 10-K. Despite the notice, there is no immediate impact on its stock listing, and the company is optimistic about its recent financing and acquisition.
Read more →-IVF
Apr 29, 2026INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K
INVO Fertility has received a notification from Nasdaq regarding its late filing of the Annual Report for the fiscal year ended December 31, 2025. The company is currently addressing complex accounting issues and plans to file the report as soon as possible. Despite this notification, INVO's stock remains listed on Nasdaq, and the company has a 60-day window to submit a compliance plan.
Read more →-IVF
Mar 25, 2026▼ -6.2%on this news· ran to -32% by day 3shared move
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
INVO Fertility, Inc. announced a 1-for-5 reverse stock split effective March 27, 2026. This move is aimed at enhancing the company's capital structure and market presence. Post-split, the company's common stock will continue trading under the ticker 'IVF'. The reverse split will reduce the number of outstanding shares while adjusting the authorized shares accordingly.
Read more →-IVF
Mar 5, 2026INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic
INVO Fertility has announced the integration of time-lapse incubation technology at its Wisconsin clinic, enhancing embryo monitoring and assessment. This technology allows for continuous observation of embryo development, supporting informed clinical decisions. Patients will benefit from increased engagement through video records of their embryos, reflecting INVO's commitment to quality and innovative care.
Read more →-IVF
Mar 3, 2026▼ -7%on this newsshared move
INVO Fertility’s Wisconsin Clinic Joins Progyny Network
INVO Fertility's Wisconsin Fertility Institute has joined the Progyny network, enhancing access to employer-sponsored fertility benefits for patients. This partnership allows WFI to provide a comprehensive suite of reproductive services and significantly increases its addressable market. The collaboration aims to improve patient care and support INVO Fertility's growth strategy.
Read more →-IVF
Feb 19, 2026INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility has completed the acquisition of Family Beginnings, a well-regarded fertility clinic in Indiana. This acquisition is part of INVO's strategy to expand its network of fertility care centers. Family Beginnings is known for its personalized approach and comprehensive services, which will now benefit from INVO's resources. The clinic's existing leadership will remain in place to ensure continuity of care.
Read more →-IVF
Feb 19, 2026INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic "Family Beginnings" Transaction Advances Company's Growth
INVO Fertility, Inc. has successfully completed the acquisition of Family Beginnings, a renowned fertility clinic in Indiana. This strategic move aims to enhance INVO's network of fertility centers, thereby expanding patient access to comprehensive reproductive services. Family Beginnings is recognized for its quality care and has generated significant revenue, contributing positively to INVO's financial performance. The acquisition is expected to further bolster INVO's operations and align with its commitment to patient-centered fertility care.
Read more →-IVF
Feb 11, 2026INVO Fertility Announces Patent Issuance for Modified INVOcell® Device
INVO Fertility has announced the issuance of a U.S. patent for a modified version of its INVOcell device, effective February 10, 2026. This patent secures intellectual property protection until 2040 and reflects the company's commitment to innovation in assisted reproductive technology. The modified INVOcell design simplifies the device for improved patient experience.
Read more →-IVF
Feb 4, 2026▼ -7.8%on this news
INVO Fertility Issues Shareholder Letter Highlighting Strengthened Fundamental Position and Strategic Outlook for Growth
INVO Fertility, Inc. has issued a shareholder letter detailing its strengthened position and growth strategy. The company has achieved profitability at its clinics and is set to acquire a fourth clinic in Indianapolis. With a focus on organic growth and acquisitions, INVO aims to expand its operational footprint and enhance its revenue base. The CEO expresses optimism about the company's future, supported by a strong balance sheet and favorable policy changes in fertility care.
Read more →-IVF
Jan 29, 2026▼ -13%on this news· ran to -28% by day 3
INVO Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
INVO Fertility Inc. has entered a warrant inducement agreement to exercise outstanding warrants, generating approximately $7.5 million. The investor will acquire shares at a reduced price of $1.59 each. Additionally, new warrants will be issued, pending shareholder approval. The transaction is expected to close around January 30, 2026.
Read more →-IVF
Jan 13, 2026INVO Fertility to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
INVO Fertility, Inc. will participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026. The company focuses on establishing and operating fertility clinics, particularly offering the innovative intravaginal culture procedure through its INVOcell device. The webcast is scheduled for 3:00 p.m. ET and will be accessible online.
Read more →-IVF
Dec 30, 2025▼ -7.7%on this news
INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy
INVO Fertility has announced a restructuring of its executive leadership to support its growth strategy in the fertility sector. Terah Krigsvold has been appointed as the new CFO, while Andrea Goren transitions to chief business officer. This realignment is aimed at enhancing the company's ability to execute its plans for acquisitions and new clinic launches.
Read more →-IVF
Dec 30, 2025▲ +10%on this news· ran to +36% by day 3shared move
INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy Krigsvold to replace Andrea Goren as CFO, who is named chief business officer and CEO of INVO Centers LLC to focus on growth efforts
INVO Fertility, Inc. has announced a restructuring of its executive leadership to support its growth strategy in the fertility sector. Terah Krigsvold replaces Andrea Goren as CFO, while Goren takes on the role of chief business officer and CEO of INVO Centers LLC. The changes aim to enhance the company's ability to acquire and establish fertility clinics, with Goren focusing on new clinic launches and strategic partnerships. This realignment is part of INVO's overall strategy to expand its presence and profitability in the fertility market.
Read more →About INVO Fertility, Inc.
Headquarters5582 BROADCAST COURT, SARASOTA, FL, 34240
BIOPHARMAWATCH ELITE PLUS
Trade the next IVF catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime